1. The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD
- Author
-
Yoon-Keun Kim, Young Koo Jee, Yeon-Mok Oh, Goohyeon Hong, You-Sun Kim, Young Min Kim, and Doh Hyung Kim
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Clinical Biochemistry ,lcsh:Medicine ,Inflammation ,Placebo ,Biochemistry ,Gastroenterology ,Article ,Pulmonary function testing ,lcsh:Biochemistry ,Alveolar cells ,03 medical and health sciences ,Mice ,Pulmonary Disease, Chronic Obstructive ,Internal medicine ,Medicine ,Animals ,Humans ,lcsh:QD415-436 ,Respiratory system ,Adverse effect ,Molecular Biology ,Lung ,Administration, Intranasal ,Aged ,COPD ,Pancreatic Elastase ,business.industry ,Macrophages ,lcsh:R ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Mice, Inbred C57BL ,030104 developmental biology ,medicine.anatomical_structure ,Pulmonary Emphysema ,Molecular Medicine ,Female ,Fibroblast Growth Factor 2 ,Tobacco Smoke Pollution ,medicine.symptom ,business - Abstract
Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated in previous studies, knowledge of its role in COPD remains limited. The mechanism of FGF2 in a COPD mouse model and the therapeutic potential of rFGF-2 were investigated in COPD. The mechanism and protective effects of rFGF-2 were evaluated in cigarette smoke-exposed or elastase-induced COPD animal models. Inflammation was assessed in alveolar cells and lung tissues from mice. FGF-2 was decreased in the lungs of cigarette smoke-exposed mice. Intranasal use of rFGF-2 significantly reduced macrophage-dominant inflammation and alveolar destruction in the lungs. In the elastase-induced emphysema model, rFGF-2 improved regeneration of the lungs. In humans, plasma FGF-2 was decreased significantly in COPD compared with normal subjects (10 subjects, P = 0.037). The safety and efficacy of inhaled rFGF-2 use was examined in COPD patients, along with changes in respiratory symptoms and pulmonary function. A 2-week treatment with inhaled rFGF-2 in COPD (n = 6) resulted in significantly improved respiratory symptoms compared with baseline levels (P, Lung disease: Inhaling a protein might help Studies on the role of the protein ‘fibroblast growth factor-2’ (FGF-2) in chronic obstructive pulmonary disease (COPD) suggest that inhaled FGF-2 could help treat the emphysema linked to smoking. Researchers in South Korea led by Young-Koo Jee at Dankook University, Cheonan, and Yeon-Mok Oh at the University of Ulsan, Seoul, studied the role of the reduced FGF-2 levels found in mice with lung inflammation caused by exposure to cigarette smoke. They also uncovered details of a protective effect of inhaled FGF-2, identifying specific cellular and lung structure changes attributed to the administered FGF-2. Reduced FGF-2 levels were also found in patients with COPD. Initial trials revealed some improvement in patients treated with FGF-2, but not at a statistically significant level. Nevertheless, the authors suggest their results justify further investigation of the protein’s therapeutic potential.
- Published
- 2018